P HEM-ONC - sarcomas are at lower risk of complications from FEB Np

 A

Here’s a summary table based on the study:
"The Performance of the Australian–UK–Swiss Clinical Decision Rule for Febrile Neutropenia in Children and Young Adults With Bone and Soft Tissue Sarcomas"

---

📊 Summary Table – Febrile Neutropenia Risk Stratification in Pediatric Sarcoma Patients

Theme	Key Insights	Key Findings / Quotes
Study Objective	To evaluate the validity and accuracy of the Australian–UK–Swiss Clinical Decision Rule (CDR) in predicting risk in children and young adults with sarcoma who develop febrile neutropenia (FN).	- Focused on risk classification to guide treatment intensity and hospital stay.
Clinical Decision Rule (CDR)	The CDR includes variables like blood counts, clinical features, and illness severity to classify patients into low-risk or high-risk for severe FN outcomes.	"The decision rule was designed to support early discharge or outpatient care in low-risk patients."
Population Studied	Children and young adults diagnosed with bone and soft tissue sarcomas, a subgroup with unique FN risks due to treatment intensity and disease biology.	- Special attention given to sarcoma-specific outcomes.
Performance of the CDR	The rule showed moderate sensitivity and specificity in identifying low-risk FN episodes, but missed a small number of serious events.	"While the CDR correctly identified a substantial proportion of low-risk cases, its false-negative rate was non-negligible."
Clinical Utility	The CDR has potential for safe early discharge in select sarcoma patients but should be applied with caution and clinical oversight.	"Clinical judgment remains essential when applying decision rules in high-risk oncology populations."
Recommendations	Further validation in larger sarcoma cohorts and consideration of sarcoma-specific variables may improve safety and accuracy.	- Consider modifications or sarcoma-specific CDRs.

---

Would you like this adapted into an infographic slide or a summary card for WhatsApp/PowerPoint?